Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy.
Jenny SchunkeVolker MailänderKatharina LandfesterMichael FichterPublished in: International journal of molecular sciences (2023)
Finding a long-term cure for tumor patients still represents a major challenge. Immunotherapies offer promising therapy options, since they are designed to specifically prime the immune system against the tumor and modulate the immunosuppressive tumor microenvironment. Using nucleic-acid-based vaccines or cellular vaccines often does not achieve sufficient activation of the immune system in clinical trials. Additionally, the rapid degradation of drugs and their non-specific uptake into tissues and cells as well as their severe side effects pose a challenge. The encapsulation of immunomodulatory molecules into nanocarriers provides the opportunity of protected cargo transport and targeted uptake by antigen-presenting cells. In addition, different immunomodulatory cargos can be co-delivered, which enables versatile stimulation of the immune system, enhances anti-tumor immune responses and improves the toxicity profile of conventional chemotherapeutic agents.
Keyphrases
- induced apoptosis
- clinical trial
- nucleic acid
- immune response
- cancer therapy
- cell cycle arrest
- drug delivery
- end stage renal disease
- oxidative stress
- chronic kidney disease
- newly diagnosed
- gene expression
- endoplasmic reticulum stress
- cell death
- early onset
- signaling pathway
- inflammatory response
- patient reported outcomes
- study protocol
- drug induced
- smoking cessation
- double blind
- quantum dots